Lorlatinib Versus Crizotinib in Patients With Advanced &lt;i&gt;ALK&lt;/i&gt;-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
Pfizer
Benjamin J Solomon; Geoffrey Liu; Enriqueta Felip; Tony S K Mok; Ross A Soo; Julien Mazieres; Alice T Shaw; Filippo de Marinis; Yasushi Goto; Yi-Long Wu; Dong-Wan Kim; Jean-François Martini; Rossella Messina; Jolanda Paolini; Anna Polli; Despina Thomaidou; Francesca Toffalorio; Todd M Bauer